[{"id":"b91c94f1-41f7-4fe2-83f9-441496a86f3f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05919537","created_at":"2023-06-26T14:09:25.129Z","updated_at":"2025-02-25T15:13:34.765Z","phase":"Phase 1","brief_title":"Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation","source_id_and_acronym":"NCT05919537","lead_sponsor":"Hummingbird Bioscience","biomarkers":" ERBB3 • NRG1 • EGF","pipe":" | ","alterations":" NRG1 fusion","tags":["ERBB3 • NRG1 • EGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRG1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e gemcitabine • docetaxel • albumin-bound paclitaxel • HMBD-001"],"overall_status":"Recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 09/06/2023","start_date":" 09/06/2023","primary_txt":" Primary completion: 03/01/2031","primary_completion_date":" 03/01/2031","study_txt":" Completion: 03/01/2031","study_completion_date":" 03/01/2031","last_update_posted":"2025-02-13"},{"id":"af4c7cda-c517-4da6-b8c2-a10bb4a3610e","acronym":"","url":"https://clinicaltrials.gov/study/NCT04100694","created_at":"2021-01-18T20:03:38.689Z","updated_at":"2025-02-25T16:44:42.630Z","phase":"","brief_title":"Early Access Program Providing HER2/HER3 Bispecific Antibody, MCLA-128, for a Patient With Advanced NRG1-Fusion Positive Solid Tumor","source_id_and_acronym":"NCT04100694","lead_sponsor":"Merus N.V.","biomarkers":" NRG1","pipe":" | ","alterations":" NRG1 fusion","tags":["NRG1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRG1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bizengri (zenocutuzumab-zbco)"],"overall_status":"Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2025-02-05"},{"id":"021a5f18-f5e7-498d-a188-e4903f2c76f5","acronym":"","url":"https://clinicaltrials.gov/study/NCT05588609","created_at":"2022-10-20T14:11:50.019Z","updated_at":"2025-02-25T16:54:29.545Z","phase":"Phase 2","brief_title":"Study Evaluating Zenocutuzumab in Patients With or Without Molecularly Defined Cancers","source_id_and_acronym":"NCT05588609","lead_sponsor":"Merus N.V.","biomarkers":" NRG1","pipe":" | ","alterations":" NRG1 fusion","tags":["NRG1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRG1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gilotrif (afatinib) • Xtandi (enzalutamide) • abiraterone acetate • Bizengri (zenocutuzumab-zbco)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 90","initiation":"Initiation: 11/17/2022","start_date":" 11/17/2022","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 03/01/2026","study_completion_date":" 03/01/2026","last_update_posted":"2025-02-04"},{"id":"9af50d59-4329-43d7-9f47-4b35e0e157f1","acronym":"eNRGy","url":"https://clinicaltrials.gov/study/NCT02912949","created_at":"2021-01-18T14:18:00.437Z","updated_at":"2025-02-25T16:59:16.918Z","phase":"Phase 2","brief_title":"A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (eNRGy)","source_id_and_acronym":"NCT02912949 - eNRGy","lead_sponsor":"Merus N.V.","biomarkers":" NRG1","pipe":" | ","alterations":" NRG1 fusion","tags":["NRG1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRG1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bizengri (zenocutuzumab-zbco)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 250","initiation":"Initiation: 01/01/2015","start_date":" 01/01/2015","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-03"},{"id":"4a5c5303-d2d6-439b-bd1d-a7d077defa4f","acronym":"CRESTONE","url":"https://clinicaltrials.gov/study/NCT04383210","created_at":"2021-01-17T17:39:01.678Z","updated_at":"2024-07-02T16:35:40.595Z","phase":"Phase 2","brief_title":"Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid Tumors","source_id_and_acronym":"NCT04383210 - CRESTONE","lead_sponsor":"Elevation Oncology","biomarkers":" NRG1","pipe":" | ","alterations":" NRG1 fusion","tags":["NRG1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRG1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e seribantumab (MM-121)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 75","initiation":"Initiation: 09/29/2020","start_date":" 09/29/2020","primary_txt":" Primary completion: 01/01/2025","primary_completion_date":" 01/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2023-08-08"},{"id":"ca5731f4-d6d7-4d7f-a3e2-390ca029a12d","acronym":"CRUKD/22/002","url":"https://clinicaltrials.gov/study/NCT05057013","created_at":"2021-09-27T12:52:51.886Z","updated_at":"2024-07-02T16:35:52.785Z","phase":"Phase 1/2","brief_title":"HMBD-001 in Advanced HER3 Positive Solid Tumours","source_id_and_acronym":"NCT05057013 - CRUKD/22/002","lead_sponsor":"Cancer Research UK","biomarkers":" ERBB3 • NRG1","pipe":" | ","alterations":" ERBB3 expression • RAS wild-type • NRG1 fusion • ERBB3 overexpression","tags":["ERBB3 • NRG1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ERBB3 expression • RAS wild-type • NRG1 fusion • ERBB3 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HMBD-001"],"overall_status":"Recruiting","enrollment":" Enrollment 135","initiation":"Initiation: 11/10/2021","start_date":" 11/10/2021","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2023-03-21"},{"id":"d4e4da76-cef2-4f4b-85c3-8bdc313c9afc","acronym":"","url":"https://clinicaltrials.gov/study/NCT05107193","created_at":"2021-11-04T16:57:15.683Z","updated_at":"2024-07-02T16:36:00.743Z","phase":"","brief_title":"Afatinib (GILOTRIF®) in Patients Suffering From Tumors Harboring Neuregulin 1 (NRG1) Gene Alterations (Specifically NRG1 Gene Fusion-positive Advanced Solid Tumors)","source_id_and_acronym":"NCT05107193","lead_sponsor":"Boehringer Ingelheim","biomarkers":" NRG1 • EGF","pipe":" | ","alterations":" NRG1 fusion","tags":["NRG1 • EGF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRG1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gilotrif (afatinib)"],"overall_status":"No Longer Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2022-11-08"},{"id":"7747fe7b-f409-46e3-82cb-5ebc290a5a68","acronym":"","url":"https://clinicaltrials.gov/study/NCT04750824","created_at":"2021-02-11T12:52:55.716Z","updated_at":"2024-07-02T16:36:18.312Z","phase":"","brief_title":"Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S.","source_id_and_acronym":"NCT04750824","lead_sponsor":"Boehringer Ingelheim","biomarkers":" NRG1","pipe":" | ","alterations":" NRG1 fusion","tags":["NRG1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRG1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gilotrif (afatinib)"],"overall_status":"Completed","enrollment":" Enrollment 110","initiation":"Initiation: 10/15/2020","start_date":" 10/15/2020","primary_txt":" Primary completion: 12/20/2021","primary_completion_date":" 12/20/2021","study_txt":" Completion: 12/20/2021","study_completion_date":" 12/20/2021","last_update_posted":"2022-01-19"},{"id":"fae4225c-f50d-4349-98d6-0d2136339eea","acronym":"","url":"https://clinicaltrials.gov/study/NCT04814056","created_at":"2021-03-24T15:11:24.734Z","updated_at":"2024-07-02T16:36:32.514Z","phase":"Phase 4","brief_title":"To Evaluate the Efficacy of Afatinib in the Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer With NRG1 Fusion","source_id_and_acronym":"NCT04814056","lead_sponsor":"Shanghai Chest Hospital","biomarkers":" NRG1","pipe":" | ","alterations":" NRG1 fusion • NRG1 fusion","tags":["NRG1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NRG1 fusion • NRG1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Gilotrif (afatinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 06/01/2021","start_date":" 06/01/2021","primary_txt":" Primary completion: 09/29/2023","primary_completion_date":" 09/29/2023","study_txt":" Completion: 01/31/2024","study_completion_date":" 01/31/2024","last_update_posted":"2021-04-01"}]